168 related articles for article (PubMed ID: 29299164)
1. XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.
Crochiere ML; Hannus S; Hansen K; Becker F; Baloglu E; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2017 Dec; 8(66):110503-110516. PubMed ID: 29299164
[TBL] [Abstract][Full Text] [Related]
2. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
4. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
5. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
6. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
7. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
10. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.
Baek HB; Lombard AP; Libertini SJ; Fernandez-Rubio A; Vinall R; Gandour-Edwards R; Nakagawa R; Vidallo K; Nishida K; Siddiqui S; Wettersten H; Landesman Y; Weiss RH; Ghosh PM; Mudryj M
Oncotarget; 2018 Oct; 9(77):34567-34581. PubMed ID: 30349650
[TBL] [Abstract][Full Text] [Related]
11. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA; Fung HY; Ranganathan P; Mitchell S; El-Gamal D; Woyach JA; Williams K; Goettl VM; Smith J; Yu X; Meng X; Sun Q; Cagatay T; Lehman AM; Lucas DM; Baloglu E; Shacham S; Kauffman MG; Byrd JC; Chook YM; Garzon R; Lapalombella R
Leukemia; 2016 Dec; 30(12):2364-2372. PubMed ID: 27323910
[TBL] [Abstract][Full Text] [Related]
12. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
13. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
14. The past, present, and future of CRM1/XPO1 inhibitors.
Wang AY; Liu H
Stem Cell Investig; 2019; 6():6. PubMed ID: 30976603
[TBL] [Abstract][Full Text] [Related]
15. Selinexor inhibits growth of patient derived chordomas
Walker CJ; Chang H; Henegar L; Kashyap T; Shacham S; Sommer J; Wick MJ; Levy J; Landesman Y
Front Oncol; 2022; 12():808021. PubMed ID: 36059685
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
17. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.
Muz B; Azab F; de la Puente P; Landesman Y; Azab AK
Transl Oncol; 2017 Aug; 10(4):632-640. PubMed ID: 28668761
[TBL] [Abstract][Full Text] [Related]
18. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
Aboukameel A; Muqbil I; Baloglu E; Senapedis W; Landesman Y; Argueta C; Kauffman M; Chang H; Kashyap T; Shacham S; Neggers JE; Daelemans D; Heath EI; Azmi AS
Oncotarget; 2018 Oct; 9(82):35327-35342. PubMed ID: 30450161
[TBL] [Abstract][Full Text] [Related]
20. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.
Soung YH; Kashyap T; Nguyen T; Yadav G; Chang H; Landesman Y; Chung J
Oncotarget; 2017 Aug; 8(32):52935-52947. PubMed ID: 28881784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]